GB Sciences Stock Price, News & Analysis

Gb Sciences is developing non-psychedelic, kava-inspired treatments aimed at addressing the global challenge of anxiety and depression affecting 300 million people. The company has received positive preclinical results supporting the efficacy of its proprietary formulas, enhancing mood without hallucinogenic effects. Leveraging its AI-enabled drug discovery technology, Gb Sciences aims to compete in the billion-dollar psychedelic market by offering alternative solutions as clinical treatments remain limited. Ongoing tests are conducted with the National Research Council of Canada.

Gb Sciences has co-published a study in Food and Chemical Toxicology demonstrating selected cannabinoids' potential to reduce inflammation. Led by Dr. Andrea Small-Howard, the research indicates that Cannabis compounds may offer better side effect profiles than traditional NSAIDs. The anti-inflammatory market is projected to grow to $191.42 billion by 2027 due to increasing chronic inflammatory disorders. The study found that delta-9 THC was most effective in modulating immune responses, with follow-up research planned on proprietary mixtures of cannabinoids.

Gb Sciences presented its AI-enabled drug discovery platform, PhAROS, at the 10th Annual Drug Discovery Strategic Summit in San Francisco. Dr. Andrea Small-Howard, the company’s President and Chief Science Officer, highlighted case studies showcasing how PhAROS identifies novel plant-inspired therapies. The platform integrates traditional plant-based knowledge with modern drug discovery techniques to expedite the development of therapies for chronic pain, anxiety, and depression. Gb Sciences aims to address critical medical needs with its proprietary technology.

Gb Sciences, a biopharmaceutical company, has achieved significant progress in its anxiety formulations during preclinical studies at the National Research Council of Canada. Utilizing its AI-driven PhAROS™ platform, the company reports a statistically significant reduction in stress in zebrafish models. These formulations are derived from traditional kava mixtures but modified to reduce toxicity risks. This marks the first advancement of Gb Sciences' non-cannabis formulations in preclinical studies, highlighting the potential of its innovative plant-inspired drug candidates.

Gb Sciences showcased their innovative approach to developing cannabinoid-based therapeutics at the Canna Pharma 2022 Conference. Dr. Andrea Small-Howard highlighted their proprietary minimal essential mixture (MEM) method, aimed at creating disease-specific therapies for conditions like Parkinson's disease and chronic pain. This method combines the benefits of whole plant extracts with the safety, consistency, and regulatory advantages of single ingredient drugs. The company is advancing five preclinical programs, with its lead Parkinson's treatment preparing for clinical trials.

Gb Sciences has co-published research in Frontiers in Pharmacology validating cannabinoid ratio-controlled, Minimum Essential Mixtures (MEM) for treating symptoms of Parkinson's disease (PD). This innovative approach targets a growing market projected to reach $8.8 billion by 2026.

Dr. Andrea Small Howard highlighted the efficacy of these mixtures in reducing PD motor symptoms in animal models. The study utilized advanced methods at multiple research sites, paving the way for further preclinical testing and potential future human trials.

Gb Sciences is intensifying efforts to advance its lead formulations for Parkinson's disease, with positive results from Oral Dissolving Tablets for upcoming human trials. Recent findings also validate anxiety formulations' efficacy and improve stability in chronic pain treatments using oral nanoparticle technology. Their drug development approach combines traditional plant-based medicine with modern drug discovery tools, showcasing a robust pipeline featuring preclinical studies for various conditions. The company aims to address critical medical needs with novel therapeutic solutions.

Gb Sciences is advancing in the life sciences sector with its innovative digital research platform, PhAROS™. Launched ahead of the pandemic, PhAROS™ leverages data analytics and machine learning to enhance drug development, targeting complex diseases through plant-inspired formulations. Recent studies show 80% of biopharma executives believe faster digital adoption is crucial. Gb Sciences has identified patent-pending formulations for various illnesses, including chronic pain and COVID-related conditions, while the company prepares for a first-in-human trial for its Parkinson’s disease therapy.

Gb Sciences is pioneering digital transformation in the biopharmaceutical sector with its innovative Phytomedical Analytics for Research Optimization at Scale (PhAROS™) platform. This technology leverages data analytics and machine learning to expedite drug development processes, offering a competitive advantage in a market where 80% of biopharma executives recognize the need for faster digital adoption. Gb Sciences' research portfolio includes patent-pending treatments for conditions like anxiety, chronic pain, and COVID-19-related cytokine release syndrome, showcasing its commitment to delivering effective, plant-inspired therapies.